Mohit Bansal
Stock Analyst at Wells Fargo
(4.28)
# 398
Out of 5,147 analysts
198
Total ratings
68.42%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $235 → $250 | $190.02 | +31.57% | 4 | Feb 25, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $69.53 | +7.87% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $388.16 | -3.39% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $61.73 | +21.50% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $132.25 | +32.33% | 8 | Feb 13, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $150 → $165 | $148.95 | +10.78% | 14 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $200 | $191.82 | +4.26% | 16 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $55 → $60 | $62.37 | -3.80% | 11 | Feb 6, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,200 → $1,280 | $1,051.99 | +21.67% | 19 | Feb 5, 2026 | |
| MRK Merck & Co. | Maintains: Overweight | $125 → $135 | $123.82 | +9.03% | 13 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $745 → $800 | $781.67 | +2.34% | 22 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $3.42 | +46.20% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.71 | +367.84% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $496.83 | +3.66% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $29.26 | +87.97% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $232.08 | +12.03% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $29.79 | +17.49% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $110.23 | +36.08% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $43.23 | +8.72% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $16.59 | +80.83% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $40.79 | +71.61% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $27.65 | +8.50% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $30.22 | +6,104.50% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $3.92 | +818.37% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $9.05 | +109.94% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.16 | +5,072.41% | 4 | Dec 3, 2019 |
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $235 → $250
Current: $190.02
Upside: +31.57%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $69.53
Upside: +7.87%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $388.16
Upside: -3.39%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $61.73
Upside: +21.50%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $132.25
Upside: +32.33%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $148.95
Upside: +10.78%
Biogen
Feb 9, 2026
Maintains: Equal-Weight
Price Target: $190 → $200
Current: $191.82
Upside: +4.26%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $62.37
Upside: -3.80%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $1,051.99
Upside: +21.67%
Merck & Co.
Feb 4, 2026
Maintains: Overweight
Price Target: $125 → $135
Current: $123.82
Upside: +9.03%
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $745 → $800
Current: $781.67
Upside: +2.34%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $3.42
Upside: +46.20%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.71
Upside: +367.84%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $496.83
Upside: +3.66%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $29.26
Upside: +87.97%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $232.08
Upside: +12.03%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $29.79
Upside: +17.49%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $110.23
Upside: +36.08%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $43.23
Upside: +8.72%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $16.59
Upside: +80.83%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $40.79
Upside: +71.61%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $27.65
Upside: +8.50%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $30.22
Upside: +6,104.50%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $3.92
Upside: +818.37%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $9.05
Upside: +109.94%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.16
Upside: +5,072.41%